

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
22 July 2021 (22.07.2021)



(10) International Publication Number  
**WO 2021/146441 A1**

(51) International Patent Classification:

C07K 7/08 (2006.01) C07K 7/02 (2006.01)  
C07K 7/04 (2006.01)

(21) International Application Number:

PCT/US2021/013463

(22) International Filing Date:

14 January 2021 (14.01.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/961,624 15 January 2020 (15.01.2020) US

(71) Applicants: JANSSEN BIOTECH, INC. [US/US];  
800/850 Ridgeview Drive, Horsham, Pennsylvania  
19044 (US). PROTAGONIST THERAPEUTICS, INC.  
[US/US]; 7707 Gateway Boulevard, Suite 140, Newark,  
California 94560 (US).

(72) Inventors: SUN, Chengzao; 800/850 Ridgeview Drive,  
Horsham, Pennsylvania 19044 (US). FREDERICK, Brian  
Troy; 7707 Gateway Boulevard, Suite 140, Newark,  
California 94560 (US). SOMANI, Sandeep; 800/850  
Ridgeview Drive, Horsham, Pennsylvania 19044 (US).  
BOURNE, Gregory Thomas; 7707 Gateway Boulevard,  
Suite 140, Newark, California 94560 (US). PATCH, Ray-  
mond; 800/850 Ridgeview Drive, Horsham, Pennsylv-  
ania 19044 (US). BHANDARI, Ashok; 7707 Gateway  
Boulevard, Suite 140, Newark, California 94560 (US).  
INGENITO, Raffaele; Via Pontina Km 30, 600-00071  
Pomezia (IT). COSTANTE, Roberto; Via Pontina Km 30,  
600-00071 Pomezia (IT). BRANCA, Danila; Via Pontina  
Km 30, 600-00071 Pomezia (IT). BIANCHI, Elisabetta;  
Via Pontina Km 30, 600-00071 Pomezia (IT).

(74) Agent: TRIMBLE, Alexander R. et al.; One Financial  
Center, Boston, Massachusetts 02111 (US).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,  
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,  
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,  
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,  
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,  
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,  
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,  
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,  
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,  
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,  
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,  
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

WO 2021/146441 A1

(54) Title: PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES

(57) Abstract: The present invention provides novel peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel diseases.